Amgen’s ( NASDAQ: AMGN ) great new hope–the bone drug Prolia –won priority review at the

Will Roche hang on to Avastin ‘s breast-cancer indication? That’s the question

Amgen (Nasdaq: AMGN) announced that the U.S. Food and Drug Administration (FDA) has granted priority review designation to denosumab, a subcutaneous RANK Ligand inhibitor, for the treatment of bone metastases to reduce skeletal related events (SREs) in patients with cancer.

Original Source of FDA Grants Priority Review Designation to Denosumab…

Embattled Johnson & Johnson ( NYSE: JNJ ), already under intense scrutiny over conditions at a Pennsylvania plant that makes children’s pain and cold drugs, is now being cited for problems at another one of its plants, CNNMoney is reporting. It marks the latest problem for the beleaguered drug…

It’s Day 2 after the Avandia vote, and the fallout continues.

Eli Lilly is letting go 340 of its IT personnel as part of a reorganization announced last fall to trim 5,500 jobs. Report

Original Source of Lilly layoffs extend to 340 IT workers

After a recent study suggested that the angiotensin receptor blockers–including Novartis’ Diovan and Merck’s Cozaar –carry an increased risk of cancer, the FDA has decided to follow up on that research with a review of its own. The agency says it’s putting ARBs under a safety review, with plans…

Sanofi-Aventis is two steps closer to getting its atrial fibrillation drug Multaq onto formularies in Europe. The U.K.’s National Institute for Health and Clinical Excellence gave Multaq its final recommendation for use by the National Health Service, with final guidance expected next month. And French authorities have upped their…

Elan has joined the marketing-settlement club. The Irish drugmaker has agreed to pay $203.5 million to settle U.S. government probes into its sales and marketing tactics on the epilepsy drug Zonegran.

Johnson & Johnson ( NYSE: JNJ )